Chongqing Sintaho Pharmaceutical Co., Ltd., founded in 2016, is a high-tech and international enterprise focusing on API R&D and manufacturing, located in Chongqing International Biological City and covering an area of 83 acres. Its holding company - Chongqing Taihao Pharmaceutical Co., Ltd., has been inspected successfully by National Medical Products Administration (NMPA), U.S. Food and Drug Administration (FDA), European Directorate for Quality Medicines (EDQM), Pharmaceuticals and Medical Devices Agency (PMDA) and etc.
Sintaho has built high standard production lines for highly active and toxic APIs in accordance with the international and domestic cGMPs, with a professional EHS and cGMP team covering R&D, production, quality management and regulatory registration, which comprehensively upgrades the management system in accordance with the cGMP regulations, ICH guidelines and EHS management standards, based on years of experience. Sintaho has been committed to building a high-end CDMO platform for oncology APIs with industry influence to produce high quality pharmaceuticals to improve human health.
Sintaho strictly controls the environment,,
health and safety (EHS) to ensure its safety,
environmental and health compliance through regular internal and external audits.
Sintaho fully implements and strictly follows cGMP and ICH guidelines.
The quality management team has rich experience on inspections of NMPA,
US FDA, EDQM, PMDA and other authorities.
近日,重庆兴泰濠制药有限公司(以下简称“兴泰濠”)与上海诗健生物科技有限公司(以下简称“诗健生物”)全面达成战略合作,双方将充分发挥兴泰濠在功能性小分子化合物的研发及生产、高活性抗肿瘤药生产、cGMP
“生产经营单位的从业人员有依法获得安全生产保障的权利,并应当依法履行哪方面的义务?”在101车间,抽到题目的化学合成员沈杰正聚精会神沉着答题,力拼得分兑换精美奖品,引得同事围观,纷纷参与其中。
重庆兴泰濠制药有限公司合成车间一原料药生产线技改项目环境影响评价公众参与报批前公示根据《中华人民共和国环境影响评价法》及《环境影响评价公众参与办法》(生态环境部令 第4号)等相关规定,现公开拟报批的《